Processa Pharmaceuticals, Inc. (PCSA) 10-Year Financial Performance & Capital Metrics

PCSA •

HealthcareBiotechnologyCommercial Specialty Pharma

AboutProcessa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.Show more

Revenue $0
EBITDA -$12M -5.2%
Net Income -$12M -6.6%
EPS (Diluted) -3.87 +54.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -354.51% -98.6%
ROIC -1786.48% -69.5%
Debt/Equity 0.04 +43.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.21%

EPS CAGR

10Y-

5Y-

3Y-

TTM-6610.56%

ROCE

10Y Avg-214.83%

5Y Avg-168.57%

3Y Avg-234.64%

Latest-356.93%

Peer Comparison

Commercial Specialty Pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALKSAlkermes plc	4.98B	30.10	21.05	-5.25%	16.37%	13.28%	0.01%	0.04
ADMAADMA Biologics, Inc.	3.71B	15.57	19.22	65.15%	42.87%	48.57%	2.97%	0.24
UTHRUnited Therapeutics Corporation	21.99B	503.90	18.09	10.61%	41.94%	18.81%	4.73%
PCSAProcessa Pharmaceuticals, Inc.	114.71M	2.17	-0.56			-221.71%		0.04
UNCYUnicycive Therapeutics, Inc.	144.49M	6.93	-1.24	-100%		-89.15%		0.10
PTHSPelthos Therapeutics Inc.	85.29M	26.36	-1.95		-318.41%	-40.48%
MISTMilestone Pharmaceuticals Inc.	145.64M	1.71	-2.55	-100%		-282.97%		4.17
AMRNAmarin Corporation plc	5.74B	13.80	-3.45	-25.51%	-38.01%	-18.78%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	113.42K	5K	0	0	0	0	0	0	0	0
Revenue Growth %	-43.34%	-95.59%	-100%	-	-	-	-	-	-	-
Cost of Goods Sold+	125.88K	1.38K	0	0	0	882.06K	0	0	0	0
COGS % of Revenue	110.98%	27.62%	-	-	-	-	-	-	-	-
Gross Profit+	-12.45K	3.62K	-1.86K	-630.09K	-877.9K	-882.06K	0	0	0	0
Gross Margin %	-10.98%	72.38%	-	-	-	-	-	-	-	-
Gross Profit Growth %	-114.32%	129.07%	-151.53%	-33685.09%	-39.33%	-0.47%	100%	-	-	-
Operating Expenses+	974.71K	1.93M	1.8M	4.52M	3.94M	14.25M	12.13M	27.53M	11.46M	12.05M
OpEx % of Revenue	859.34%	38530.4%	-	-	-	-	-	-	-	-
Selling, General & Admin	945.46K	384.52K	876.32K	1.44M	1.61M	3.18M	4.69M	8.76M	5.66M	4.78M
SG&A % of Revenue	833.56%	7690.48%	-	-	-	-	-	-	-	-
Research & Development	29.25K	6.56K	926.12K	3.09M	2.32M	11.08M	6.88M	11.49M	5.8M	7.27M
R&D % of Revenue	25.78%	131.16%	-	-	-	-	-	-	-	-
Other Operating Expenses	0	1.85M	0	0	0	0	566.58K	7.27M	0	0
Operating Income+	2.69M	-1.92M	-1.8M	-4.52M	-3.94M	-15.14M	-12.13M	-27.53M	-11.46M	-12.05M
Operating Margin %	2372.57%	-38430.4%	-	-	-	-	-	-	-	-
Operating Income Growth %	164.68%	-171.4%	6.2%	-151.05%	13.03%	-284.63%	19.84%	-126.85%	58.38%	-5.19%
EBITDA+	2.93M	-1.92M	-1.8M	-3.89M	-3.06M	-14.25M	-11.34M	-26.74M	-11.46M	-12.05M
EBITDA Margin %	2583.12%	-38402.78%	-	-	-	-	-	-	-	-
EBITDA Growth %	179.2%	-165.54%	6.23%	-116.31%	21.5%	-366.21%	20.43%	-135.72%	57.15%	-5.18%
D&A (Non-Cash Add-back)	238.82K	1.38K	1.86K	630.09K	877.9K	882.06K	790.97K	788.5K	222	782
EBIT	-2.75M	-91.8K	-1.8M	-4.51M	-3.92M	-15.13M	-11.57M	-20.26M	-11.46M	-12.05M
Net Interest Income+	-230.99K	-245.38K	-30.51K	-142.91K	-25.11K	-277.95K	11.63K	101.2K	335.54K	201.09K
Interest Income	4.65K	0	5.18K	18.3K	11.55K	3.17K	11.99K	101.2K	335.54K	201.09K
Interest Expense	235.64K	245.38K	35.69K	161.21K	36.66K	281.12K	362	0	0	0
Other Income/Expense	-5.67M	4.45K	-53.88K	-142.91K	-25.11K	-277.95K	175.4K	101.2K	335.54K	201.09K
Pretax Income+	-2.98M	-337.18K	-1.86M	-4.67M	-3.96M	-15.41M	-11.96M	-27.42M	-11.12M	-11.85M
Pretax Margin %	-2629.77%	-6743.58%	-	-	-	-	-	-	-	-
Income Tax+	100	-1.2K	-18.19K	-902.8K	-602.72K	-1M	-530.61K	0	0	0
Effective Tax Rate %	112.45%	99.64%	100%	80.66%	84.78%	123.52%	95.56%	100%	100%	100%
Net Income+	-3.35M	-335.98K	-1.86M	-3.77M	-3.36M	-19.04M	-11.43M	-27.42M	-11.12M	-11.85M
Net Margin %	-2957.22%	-6719.64%	-	-	-	-	-	-	-	-
Net Income Growth %	25.89%	89.98%	-452.5%	-102.82%	10.81%	-467.02%	39.98%	-139.98%	59.45%	-6.55%
Net Income (Continuing)	-2.98M	-337.18K	-1.86M	-3.77M	-3.36M	-14.41M	-11.43M	-27.42M	-11.12M	-11.85M
Discontinued Operations	-371.31K	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-298.40	-29.89	-8.00	-14.20	-12.17	-50.77	-14.92	-1.70	-8.48	-3.87
EPS Growth %	55.22%	89.98%	73.24%	-77.5%	14.3%	-317.17%	70.61%	88.61%	-398.82%	54.36%
EPS (Basic)	-298.40	-29.89	-8.00	-14.20	-12.17	-50.77	-14.92	-1.70	-8.48	-3.87
Diluted Shares Outstanding	11.24K	11.24K	232.83K	266.61K	275.87K	374.98K	765.97K	16.11M	1.31M	3.06M
Basic Shares Outstanding	11.24K	11.24K	232.83K	266.61K	275.87K	374.98K	765.97K	16.11M	1.31M	3.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.16K	3.24K	2.95M	2.02M	1.01M	16.2M	18.33M	8.39M	5.63M	1.87M
Cash & Short-Term Investments	2.09K	3.24K	2.85M	1.74M	691.54K	15.42M	16.5M	6.5M	4.71M	1.19M
Cash Only	2.09K	3.24K	2.85M	1.74M	691.54K	15.42M	16.5M	6.5M	4.71M	1.19M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	62.71K	21.58K	0	231.75K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	54.35K	0	0	0	0	0	70.27K	0	926.3K	0
Total Non-Current Assets+	159	27.93K	31.36K	10.46M	9.88M	9.01M	8.14M	233.12K	154.15K	1.36M
Property, Plant & Equipment	159	22.39K	25.82K	17.38K	228K	159.04K	74.18K	227.59K	148.61K	75.69K
Fixed Asset Turnover	713.36x	0.22x	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	10.44M	9.64M	8.85M	8.06M	0	0	0
Long-Term Investments	0	0	0	1.8M	-1.12M	-1.9M	0	0	0	0
Other Non-Current Assets	0	5.53K	5.54K	-2.53M	5.54K	5.54K	5.54K	5.54K	5.54K	1.28M
Total Assets+	104.32K	3.24K	2.98M	13.21M	10.88M	25.21M	26.46M	8.62M	5.79M	3.23M
Asset Turnover	1.09x	1.54x	-	-	-	-	-	-	-	-
Asset Growth %	-95.9%	-96.9%	92051.37%	343.01%	-17.64%	131.68%	4.95%	-67.43%	-32.87%	-44.19%
Total Current Liabilities+	2.08M	97.69K	2.6M	645.7K	1.19M	1.22M	971.02K	998.56K	730.58K	1.53M
Accounts Payable	159.25K	166.16K	50.69K	292.1K	75.61K	320.69K	218.91K	327.55K	311.62K	880.88K
Days Payables Outstanding	461.77	43.92K	-	-	-	132.7	-	-	-	-
Short-Term Debt	1.37M	1.61M	2.45M	230K	802.5K	117.57K	0	0	0	0
Deferred Revenue (Current)	0	483.91K	0	0	0	0	0	0	0	0
Other Current Liabilities	557.28K	0	436	0	316	469.86K	401.77K	189.05K	189.04K	0
Current Ratio	0.05x	0.03x	1.14x	3.13x	0.85x	13.27x	18.87x	8.40x	7.71x	1.22x
Quick Ratio	0.05x	0.03x	1.14x	3.13x	0.85x	13.27x	18.87x	8.40x	7.71x	1.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	9.96K	2.13M	1.68M	1.05M	7.38K	150.55K	66.91K	487
Long-Term Debt	0	0	0	0	0	44.88K	0	0	0	0
Capital Lease Obligations	0	0	0	0	147.39K	78.46K	7.38K	150.55K	66.91K	487
Deferred Tax Liabilities	0	0	0	0	1.53M	530.61K	0	0	0	0
Other Non-Current Liabilities	0	0	9.96K	2.13M	0	400K	0	0	0	0
Total Liabilities	2.08M	2.35M	2.61M	3.51M	2.87M	2.27M	978.4K	1.15M	797.48K	1.53M
Total Debt+	1.37M	1.61M	2.45M	230K	1.03M	328.12K	78.46K	229.45K	150.55K	73.51K
Net Debt	1.36M	1.61M	-398.86K	-1.51M	336.35K	-15.09M	-16.42M	-6.27M	-4.56M	-1.12M
Debt / Equity	-	-	6.56x	0.02x	0.13x	0.01x	0.00x	0.03x	0.03x	0.04x
Debt / EBITDA	0.47x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	0.47x	-	-	-	-	-	-	-	-	-
Interest Coverage	11.42x	-7.83x	-50.50x	-28.07x	-107.36x	-53.84x	-33518.07x	-	-	-
Total Equity+	-1.98M	-2.35M	373.16K	9.7M	8.01M	22.94M	25.49M	7.47M	4.99M	1.7M
Equity Growth %	-263.82%	-18.82%	115.87%	2499.67%	-17.41%	186.29%	11.1%	-70.69%	-33.22%	-66%
Book Value per Share	-176.10	-209.14	1.60	36.39	29.04	61.17	33.27	0.46	3.80	0.55
Total Shareholders' Equity	-1.98M	-2.35M	373.16K	9.7M	8.01M	22.94M	25.49M	7.47M	4.99M	1.7M
Common Stock	1.1K	1.1K	3.53K	3.87K	549	1.42K	1.57K	1.61K	129	371
Retained Earnings	-14.87M	-15.25M	-3.86M	-7.62M	-10.98M	-25.4M	-36.82M	-64.25M	-75.37M	-87.22M
Treasury Stock	0	0	0	0	0	0	0	-300K	-300K	-300K
Accumulated OCI	-18.99K	-19.15K	-3.25K	-1.8M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-871.91K	-43.2K	-1.65M	-3.71M	-2.75M	-3.14M	-8.72M	-9.61M	-8.06M	-11.25M
Operating CF Margin %	-768.71%	-864.06%	-	-	-	-	-	-	-	-
Operating CF Growth %	67.65%	95.05%	-3729.87%	-124.09%	25.83%	-14.29%	-177.34%	-10.18%	16.05%	-39.46%
Net Income	-2.98M	-337.18K	-1.86M	-3.77M	-3.36M	-14.41M	-11.43M	-27.42M	-11.12M	-11.85M
Depreciation & Amortization	238.82K	159	1.86K	630.09K	803.77K	803.77K	790.97K	788.5K	222	782
Stock-Based Compensation	96.93K	6.69K	0	74.06K	510.48K	2.73M	3.41M	8.83M	1.06M	629.51K
Deferred Taxes	1.54M	7.92K	0	-902.8K	-602.72K	-1M	-530.61K	0	0	0
Other Non-Cash Items	83.3K	967	38.7K	67.07K	75.91K	8.88M	220.61K	7.66M	1.39M	87.18K
Working Capital Changes	153.5K	278.24K	161.13K	188.71K	-179.71K	-140.39K	-1.18M	543.6K	605.21K	-112.4K
Change in Receivables	213.41K	0	0	0	0	-77.02K	6.75K	70.27K	0	0
Change in Inventory	-7.07K	0	0	0	0	77.02K	-6.75K	0	0	0
Change in Payables	5.32K	-10.34K	0	241.42K	-216.49K	245.08K	-101.79K	108.64K	-15.93K	569.26K
Cash from Investing+	40.2K	17K	1M	-22.28K	0	0	0	0	-2.78K	-3.24K
Capital Expenditures	-1.4K	-23.77K	-20.62K	-22.28K	0	0	0	0	-2.78K	-3.24K
CapEx % of Revenue	1.23%	475.5%	-	-	-	-	-	-	-	-
Acquisitions	0	0	6.28K	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	41.6K	40.77K	1.02M	0	0	0	0	0	0	0
Cash from Financing+	821.1K	15K	2.43M	2.62M	1.7M	17.87M	9.8M	-388.84K	6.27M	7.73M
Debt Issued (Net)	733.1K	15K	2.58M	0	805K	862.46K	0	0	0	-5.2K
Equity Issued (Net)	88K	0	0	1000K	0	1000K	1000K	-300K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	-95.21K	-64.4K	-388.84K	0	-15.9K
Other Financing	0	0	-154.8K	-250.96K	895.72K	0	-186.49K	-88.84K	-52.75K	-8.56K
Net Change in Cash	-10.6K	-11.2K	1.78M	-1.11M	-1.05M	14.72M	1.08M	-9.99M	-1.8M	-3.51M
Free Cash Flow+	-873.3K	-66.98K	-1.68M	-3.73M	-2.75M	-3.14M	-8.72M	-9.61M	-8.07M	-11.25M
FCF Margin %	-769.94%	-1339.56%	-	-	-	-	-	-	-	-
FCF Growth %	68.17%	92.33%	-2401.18%	-122.56%	26.24%	-14.29%	-177.34%	-10.18%	16.02%	-39.45%
FCF per Share	-77.72	-5.96	-7.20	-13.98	-9.97	-8.38	-11.38	-0.60	-6.15	-3.68
FCF Conversion (FCF/Net Income)	0.26x	0.13x	0.89x	0.98x	0.82x	0.17x	0.76x	0.35x	0.73x	0.95x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-497.45%	-74.75%	-37.91%	-123.03%	-47.2%	-166.43%	-178.52%	-354.51%
Return on Invested Capital (ROIC)	263.36%	-	-	-83.13%	-35.69%	-140.15%	-107.58%	-402.32%	-1054.26%	-1786.48%
Gross Margin	-10.98%	72.38%	-	-	-	-	-	-	-	-
Net Margin	-2957.22%	-6719.64%	-	-	-	-	-	-	-	-
Debt / Equity	-	-	6.56x	0.02x	0.13x	0.01x	0.00x	0.03x	0.03x	0.04x
Interest Coverage	11.42x	-7.83x	-50.50x	-28.07x	-107.36x	-53.84x	-33518.07x	-	-	-
FCF Conversion	0.26x	0.13x	0.89x	0.98x	0.82x	0.17x	0.76x	0.35x	0.73x	0.95x
Revenue Growth	-43.34%	-95.59%	-100%	-	-	-	-	-	-	-

US Stock Screener

...

Processa Pharmaceuticals, Inc. (PCSA) 10-Year Financial Performance & Capital Metrics

PCSA •

HealthcareBiotechnologyCommercial Specialty Pharma

Revenue $0
EBITDA -$12M -5.2%
Net Income -$12M -6.6%
EPS (Diluted) -3.87 +54.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -354.51% -98.6%
ROIC -1786.48% -69.5%
Debt/Equity 0.04 +43.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-12.21%

EPS CAGR

10Y-

5Y-

3Y-

TTM-6610.56%

ROCE

10Y Avg-214.83%

5Y Avg-168.57%

3Y Avg-234.64%

Latest-356.93%

Peer Comparison

Commercial Specialty Pharma

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALKSAlkermes plc	4.98B	30.10	21.05	-5.25%	16.37%	13.28%	0.01%	0.04
ADMAADMA Biologics, Inc.	3.71B	15.57	19.22	65.15%	42.87%	48.57%	2.97%	0.24
UTHRUnited Therapeutics Corporation	21.99B	503.90	18.09	10.61%	41.94%	18.81%	4.73%
PCSAProcessa Pharmaceuticals, Inc.	114.71M	2.17	-0.56			-221.71%		0.04
UNCYUnicycive Therapeutics, Inc.	144.49M	6.93	-1.24	-100%		-89.15%		0.10
PTHSPelthos Therapeutics Inc.	85.29M	26.36	-1.95		-318.41%	-40.48%
MISTMilestone Pharmaceuticals Inc.	145.64M	1.71	-2.55	-100%		-282.97%		4.17
AMRNAmarin Corporation plc	5.74B	13.80	-3.45	-25.51%	-38.01%	-18.78%		0.02

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	113.42K	5K	0	0	0	0	0	0	0	0
Revenue Growth %	-43.34%	-95.59%	-100%	-	-	-	-	-	-	-
Cost of Goods Sold+	125.88K	1.38K	0	0	0	882.06K	0	0	0	0
COGS % of Revenue	110.98%	27.62%	-	-	-	-	-	-	-	-
Gross Profit+	-12.45K	3.62K	-1.86K	-630.09K	-877.9K	-882.06K	0	0	0	0
Gross Margin %	-10.98%	72.38%	-	-	-	-	-	-	-	-
Gross Profit Growth %	-114.32%	129.07%	-151.53%	-33685.09%	-39.33%	-0.47%	100%	-	-	-
Operating Expenses+	974.71K	1.93M	1.8M	4.52M	3.94M	14.25M	12.13M	27.53M	11.46M	12.05M
OpEx % of Revenue	859.34%	38530.4%	-	-	-	-	-	-	-	-
Selling, General & Admin	945.46K	384.52K	876.32K	1.44M	1.61M	3.18M	4.69M	8.76M	5.66M	4.78M
SG&A % of Revenue	833.56%	7690.48%	-	-	-	-	-	-	-	-
Research & Development	29.25K	6.56K	926.12K	3.09M	2.32M	11.08M	6.88M	11.49M	5.8M	7.27M
R&D % of Revenue	25.78%	131.16%	-	-	-	-	-	-	-	-
Other Operating Expenses	0	1.85M	0	0	0	0	566.58K	7.27M	0	0
Operating Income+	2.69M	-1.92M	-1.8M	-4.52M	-3.94M	-15.14M	-12.13M	-27.53M	-11.46M	-12.05M
Operating Margin %	2372.57%	-38430.4%	-	-	-	-	-	-	-	-
Operating Income Growth %	164.68%	-171.4%	6.2%	-151.05%	13.03%	-284.63%	19.84%	-126.85%	58.38%	-5.19%
EBITDA+	2.93M	-1.92M	-1.8M	-3.89M	-3.06M	-14.25M	-11.34M	-26.74M	-11.46M	-12.05M
EBITDA Margin %	2583.12%	-38402.78%	-	-	-	-	-	-	-	-
EBITDA Growth %	179.2%	-165.54%	6.23%	-116.31%	21.5%	-366.21%	20.43%	-135.72%	57.15%	-5.18%
D&A (Non-Cash Add-back)	238.82K	1.38K	1.86K	630.09K	877.9K	882.06K	790.97K	788.5K	222	782
EBIT	-2.75M	-91.8K	-1.8M	-4.51M	-3.92M	-15.13M	-11.57M	-20.26M	-11.46M	-12.05M
Net Interest Income+	-230.99K	-245.38K	-30.51K	-142.91K	-25.11K	-277.95K	11.63K	101.2K	335.54K	201.09K
Interest Income	4.65K	0	5.18K	18.3K	11.55K	3.17K	11.99K	101.2K	335.54K	201.09K
Interest Expense	235.64K	245.38K	35.69K	161.21K	36.66K	281.12K	362	0	0	0
Other Income/Expense	-5.67M	4.45K	-53.88K	-142.91K	-25.11K	-277.95K	175.4K	101.2K	335.54K	201.09K
Pretax Income+	-2.98M	-337.18K	-1.86M	-4.67M	-3.96M	-15.41M	-11.96M	-27.42M	-11.12M	-11.85M
Pretax Margin %	-2629.77%	-6743.58%	-	-	-	-	-	-	-	-
Income Tax+	100	-1.2K	-18.19K	-902.8K	-602.72K	-1M	-530.61K	0	0	0
Effective Tax Rate %	112.45%	99.64%	100%	80.66%	84.78%	123.52%	95.56%	100%	100%	100%
Net Income+	-3.35M	-335.98K	-1.86M	-3.77M	-3.36M	-19.04M	-11.43M	-27.42M	-11.12M	-11.85M
Net Margin %	-2957.22%	-6719.64%	-	-	-	-	-	-	-	-
Net Income Growth %	25.89%	89.98%	-452.5%	-102.82%	10.81%	-467.02%	39.98%	-139.98%	59.45%	-6.55%
Net Income (Continuing)	-2.98M	-337.18K	-1.86M	-3.77M	-3.36M	-14.41M	-11.43M	-27.42M	-11.12M	-11.85M
Discontinued Operations	-371.31K	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-298.40	-29.89	-8.00	-14.20	-12.17	-50.77	-14.92	-1.70	-8.48	-3.87
EPS Growth %	55.22%	89.98%	73.24%	-77.5%	14.3%	-317.17%	70.61%	88.61%	-398.82%	54.36%
EPS (Basic)	-298.40	-29.89	-8.00	-14.20	-12.17	-50.77	-14.92	-1.70	-8.48	-3.87
Diluted Shares Outstanding	11.24K	11.24K	232.83K	266.61K	275.87K	374.98K	765.97K	16.11M	1.31M	3.06M
Basic Shares Outstanding	11.24K	11.24K	232.83K	266.61K	275.87K	374.98K	765.97K	16.11M	1.31M	3.06M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.16K	3.24K	2.95M	2.02M	1.01M	16.2M	18.33M	8.39M	5.63M	1.87M
Cash & Short-Term Investments	2.09K	3.24K	2.85M	1.74M	691.54K	15.42M	16.5M	6.5M	4.71M	1.19M
Cash Only	2.09K	3.24K	2.85M	1.74M	691.54K	15.42M	16.5M	6.5M	4.71M	1.19M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	62.71K	21.58K	0	231.75K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	54.35K	0	0	0	0	0	70.27K	0	926.3K	0
Total Non-Current Assets+	159	27.93K	31.36K	10.46M	9.88M	9.01M	8.14M	233.12K	154.15K	1.36M
Property, Plant & Equipment	159	22.39K	25.82K	17.38K	228K	159.04K	74.18K	227.59K	148.61K	75.69K
Fixed Asset Turnover	713.36x	0.22x	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	10.44M	9.64M	8.85M	8.06M	0	0	0
Long-Term Investments	0	0	0	1.8M	-1.12M	-1.9M	0	0	0	0
Other Non-Current Assets	0	5.53K	5.54K	-2.53M	5.54K	5.54K	5.54K	5.54K	5.54K	1.28M
Total Assets+	104.32K	3.24K	2.98M	13.21M	10.88M	25.21M	26.46M	8.62M	5.79M	3.23M
Asset Turnover	1.09x	1.54x	-	-	-	-	-	-	-	-
Asset Growth %	-95.9%	-96.9%	92051.37%	343.01%	-17.64%	131.68%	4.95%	-67.43%	-32.87%	-44.19%
Total Current Liabilities+	2.08M	97.69K	2.6M	645.7K	1.19M	1.22M	971.02K	998.56K	730.58K	1.53M
Accounts Payable	159.25K	166.16K	50.69K	292.1K	75.61K	320.69K	218.91K	327.55K	311.62K	880.88K
Days Payables Outstanding	461.77	43.92K	-	-	-	132.7	-	-	-	-
Short-Term Debt	1.37M	1.61M	2.45M	230K	802.5K	117.57K	0	0	0	0
Deferred Revenue (Current)	0	483.91K	0	0	0	0	0	0	0	0
Other Current Liabilities	557.28K	0	436	0	316	469.86K	401.77K	189.05K	189.04K	0
Current Ratio	0.05x	0.03x	1.14x	3.13x	0.85x	13.27x	18.87x	8.40x	7.71x	1.22x
Quick Ratio	0.05x	0.03x	1.14x	3.13x	0.85x	13.27x	18.87x	8.40x	7.71x	1.22x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	9.96K	2.13M	1.68M	1.05M	7.38K	150.55K	66.91K	487
Long-Term Debt	0	0	0	0	0	44.88K	0	0	0	0
Capital Lease Obligations	0	0	0	0	147.39K	78.46K	7.38K	150.55K	66.91K	487
Deferred Tax Liabilities	0	0	0	0	1.53M	530.61K	0	0	0	0
Other Non-Current Liabilities	0	0	9.96K	2.13M	0	400K	0	0	0	0
Total Liabilities	2.08M	2.35M	2.61M	3.51M	2.87M	2.27M	978.4K	1.15M	797.48K	1.53M
Total Debt+	1.37M	1.61M	2.45M	230K	1.03M	328.12K	78.46K	229.45K	150.55K	73.51K
Net Debt	1.36M	1.61M	-398.86K	-1.51M	336.35K	-15.09M	-16.42M	-6.27M	-4.56M	-1.12M
Debt / Equity	-	-	6.56x	0.02x	0.13x	0.01x	0.00x	0.03x	0.03x	0.04x
Debt / EBITDA	0.47x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	0.47x	-	-	-	-	-	-	-	-	-
Interest Coverage	11.42x	-7.83x	-50.50x	-28.07x	-107.36x	-53.84x	-33518.07x	-	-	-
Total Equity+	-1.98M	-2.35M	373.16K	9.7M	8.01M	22.94M	25.49M	7.47M	4.99M	1.7M
Equity Growth %	-263.82%	-18.82%	115.87%	2499.67%	-17.41%	186.29%	11.1%	-70.69%	-33.22%	-66%
Book Value per Share	-176.10	-209.14	1.60	36.39	29.04	61.17	33.27	0.46	3.80	0.55
Total Shareholders' Equity	-1.98M	-2.35M	373.16K	9.7M	8.01M	22.94M	25.49M	7.47M	4.99M	1.7M
Common Stock	1.1K	1.1K	3.53K	3.87K	549	1.42K	1.57K	1.61K	129	371
Retained Earnings	-14.87M	-15.25M	-3.86M	-7.62M	-10.98M	-25.4M	-36.82M	-64.25M	-75.37M	-87.22M
Treasury Stock	0	0	0	0	0	0	0	-300K	-300K	-300K
Accumulated OCI	-18.99K	-19.15K	-3.25K	-1.8M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-871.91K	-43.2K	-1.65M	-3.71M	-2.75M	-3.14M	-8.72M	-9.61M	-8.06M	-11.25M
Operating CF Margin %	-768.71%	-864.06%	-	-	-	-	-	-	-	-
Operating CF Growth %	67.65%	95.05%	-3729.87%	-124.09%	25.83%	-14.29%	-177.34%	-10.18%	16.05%	-39.46%
Net Income	-2.98M	-337.18K	-1.86M	-3.77M	-3.36M	-14.41M	-11.43M	-27.42M	-11.12M	-11.85M
Depreciation & Amortization	238.82K	159	1.86K	630.09K	803.77K	803.77K	790.97K	788.5K	222	782
Stock-Based Compensation	96.93K	6.69K	0	74.06K	510.48K	2.73M	3.41M	8.83M	1.06M	629.51K
Deferred Taxes	1.54M	7.92K	0	-902.8K	-602.72K	-1M	-530.61K	0	0	0
Other Non-Cash Items	83.3K	967	38.7K	67.07K	75.91K	8.88M	220.61K	7.66M	1.39M	87.18K
Working Capital Changes	153.5K	278.24K	161.13K	188.71K	-179.71K	-140.39K	-1.18M	543.6K	605.21K	-112.4K
Change in Receivables	213.41K	0	0	0	0	-77.02K	6.75K	70.27K	0	0
Change in Inventory	-7.07K	0	0	0	0	77.02K	-6.75K	0	0	0
Change in Payables	5.32K	-10.34K	0	241.42K	-216.49K	245.08K	-101.79K	108.64K	-15.93K	569.26K
Cash from Investing+	40.2K	17K	1M	-22.28K	0	0	0	0	-2.78K	-3.24K
Capital Expenditures	-1.4K	-23.77K	-20.62K	-22.28K	0	0	0	0	-2.78K	-3.24K
CapEx % of Revenue	1.23%	475.5%	-	-	-	-	-	-	-	-
Acquisitions	0	0	6.28K	0	0	0	0	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	41.6K	40.77K	1.02M	0	0	0	0	0	0	0
Cash from Financing+	821.1K	15K	2.43M	2.62M	1.7M	17.87M	9.8M	-388.84K	6.27M	7.73M
Debt Issued (Net)	733.1K	15K	2.58M	0	805K	862.46K	0	0	0	-5.2K
Equity Issued (Net)	88K	0	0	1000K	0	1000K	1000K	-300K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	0	0	0	-95.21K	-64.4K	-388.84K	0	-15.9K
Other Financing	0	0	-154.8K	-250.96K	895.72K	0	-186.49K	-88.84K	-52.75K	-8.56K
Net Change in Cash	-10.6K	-11.2K	1.78M	-1.11M	-1.05M	14.72M	1.08M	-9.99M	-1.8M	-3.51M
Free Cash Flow+	-873.3K	-66.98K	-1.68M	-3.73M	-2.75M	-3.14M	-8.72M	-9.61M	-8.07M	-11.25M
FCF Margin %	-769.94%	-1339.56%	-	-	-	-	-	-	-	-
FCF Growth %	68.17%	92.33%	-2401.18%	-122.56%	26.24%	-14.29%	-177.34%	-10.18%	16.02%	-39.45%
FCF per Share	-77.72	-5.96	-7.20	-13.98	-9.97	-8.38	-11.38	-0.60	-6.15	-3.68
FCF Conversion (FCF/Net Income)	0.26x	0.13x	0.89x	0.98x	0.82x	0.17x	0.76x	0.35x	0.73x	0.95x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-497.45%	-74.75%	-37.91%	-123.03%	-47.2%	-166.43%	-178.52%	-354.51%
Return on Invested Capital (ROIC)	263.36%	-	-	-83.13%	-35.69%	-140.15%	-107.58%	-402.32%	-1054.26%	-1786.48%
Gross Margin	-10.98%	72.38%	-	-	-	-	-	-	-	-
Net Margin	-2957.22%	-6719.64%	-	-	-	-	-	-	-	-
Debt / Equity	-	-	6.56x	0.02x	0.13x	0.01x	0.00x	0.03x	0.03x	0.04x
Interest Coverage	11.42x	-7.83x	-50.50x	-28.07x	-107.36x	-53.84x	-33518.07x	-	-	-
FCF Conversion	0.26x	0.13x	0.89x	0.98x	0.82x	0.17x	0.76x	0.35x	0.73x	0.95x
Revenue Growth	-43.34%	-95.59%	-100%	-	-	-	-	-	-	-

Processa Pharmaceuticals, Inc. (PCSA) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PCSA vs Peers

vs UTHR

vs ZLAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Processa Pharmaceuticals, Inc. (PCSA) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare PCSA vs Peers

vs UTHR

vs ZLAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios